Apr 13 |
AbbVie keeps Humira market share near 100% despite biosimilars: report
|
Apr 11 |
Pfizer unit to settle Effexor XR antitrust claims in $39M deal
|
Apr 11 |
Teva confirms efficacy in late stage trial of its migraine treatment for adult Chinese patients
|
Apr 11 |
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
|
Apr 9 |
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
|
Apr 6 |
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
|
Apr 4 |
Teva and mAbxience sign global licensing agreement for oncology biosimilar candidate
|
Apr 4 |
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
|
Apr 3 |
Urogen files patent suit against Teva over cancer therapy
|
Apr 3 |
3 No-Brainer Stocks to Buy With $600 Right Now
|